The DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.
Ocular Drug Delivery Barriers—Role of Nanocarriers in the Treatment of Anterior Segment Ocular Diseases
Open accessAbstract
Ocular drug delivery is challenging due to the presence of anatomical and physiological barriers. These barriers can affect drug entry into the eye following multiple routes of administration (e.g., topical, systemic, and injectable). Topical administration in the form of eye drops is preferred for treating anterior segment diseases, as it is convenient and provides local delivery of drugs. Major concerns with topical delivery include poor drug absorption and low bioavailability. To improve the bioavailability of topically administered drugs, novel drug delivery systems are being investigated. Nanocarrier delivery systems demonstrate enhanced drug permeation and prolonged drug release. This review provides an overview of ocular barriers to anterior segment delivery, along with ways to overcome these barriers using nanocarrier systems. The disposition of nanocarriers following topical administration, their safety, toxicity and clinical trials involving nanocarrier systems are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Global estimates of visual impairment: 2010
Pascolini, D., & Mariotti, S. P. (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2011-300539 · Cited by 3,763
Block copolymer micelles for drug delivery: design, characterization and biological significance
Kataoka, K., Harada, A., & Nagasaki, Y. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00124-1 · Cited by 3,506
Solid lipid nanoparticles Production, characterization and applications
Mehnert, W. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00105-3 · Cited by 3,150
Occludin: a novel integral membrane protein localizing at tight junctions.
Furuse, M., Hirase, T., Itoh, M., Nagafuchi, A., Yonemura, S., Tsukita, S., & Tsukita, S. (1993) · The Journal of cell biology · doi:10.1083/jcb.123.6.1777 · Cited by 2,580 · cited 1×
“There are four tight junction proteins, ZO-1, cingulin, ZO-2 [7], and occluden [8], with occluden being the most important.”
BackgroundSurfactants and Interfacial Phenomena
Rosen, M. J., & Kunjappu, J. T. (2012) · Wiley eBooks · doi:10.1002/9781118228920 · Cited by 2,535
Microemulsion-based media as novel drug delivery systems
Lawrence, M. J., & Rees, G. D. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00103-4 · Cited by 2,040
Structure and design of polymeric surfactant-based drug delivery systems
Torchilin, V. P. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00299-1 · Cited by 1,822
Pluronic® block copolymers as novel polymer therapeutics for drug and gene delivery
Kabanov, A. V., Batrakova, E. V., & Alakhov, V. Y. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00009-3 · Cited by 1,474 · cited 2×
“Copolymers form non-nanomicellar structures known as rods and lamellae, with an increase in the length of hydrophobic segment [101].”
BackgroundGaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406
Cited by
Ocular drug delivery: present innovations and future challenges
Gote, V., Sikder, S., Sicotte, J., & Pal, D. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.256933 · Cited by 441
Hydrogel-based commercial products for biomedical applications: A review
Cascone, S., & Lamberti, G. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118803 · Cited by 421
Ocular Drug Delivery: a Comprehensive Review
Ahmed, S., Amin, M. M., & Sayed, S. (2023) · AAPS PharmSciTech · doi:10.1208/s12249-023-02516-9 · Cited by 352
Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases
Onugwu, A. L., Nwagwu, C. S., Onugwu, O. S., Echezona, A. C., Agbo, C. P., Ihim, S. A., Emeh, P., Nnamani, P. O., Attama, A. A., & Khutoryanskiy, V. V. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.018 · Cited by 350
Nanocarriers for ocular drug delivery: current status and translational opportunity
Gorantla, S., Rapalli, V. K., Waghule, T., Singh, P. P., Dubey, S. K., Saha, R. N., & Singhvi, G. (2020) · RSC Advances · doi:10.1039/d0ra04971a · Cited by 313
Nanotechnology-based ocular drug delivery systems: recent advances and future prospects
Li, S., Chen, L., & Fu, Y. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01992-2 · Cited by 277
Nanoparticle–hydrogel superstructures for biomedical applications
Jiang, Y., Krishnan, N., Heo, J., Fang, R. H., & Zhang, L. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.041 · Cited by 266
Gaballa, S. A., Kompella, U. B., Elgarhy, O., Alqahtani, A. M., Pierscionek, B., Alany, R. G., & Abdelkader, H. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00843-z · Cited by 255
“multiple physiological barriers including epithelial and connective tissue barriers, tear turnover, nasolacrimal drainage of the instilled dose, and potentially poor in vivo dissolution of practically insoluble corticosteroids (Table 1) [94, 100, 101].”
BackgroundSoluplus micelles for acyclovir ocular delivery: formulation and cornea and sclera permeability
Varela-Garcia, A., Concheiro, A., & Alvarez-Lorenzo, C. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.09.053 · Cited by 92
Lipid nanoparticles for the posterior eye segment
Bonilla, L., Espina, M., Severino, P., Cano, A., Ettcheto, M., Camins, A., García, M. L., Souto, E. B., & Sánchez-López, E. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010090 · Cited by 76
Micelles: promising ocular drug carriers for anterior and posterior segment diseases
Durgun, M. E., Güngör, S., & Özsoy, Y. (2020) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2019.0109 · Cited by 67
“7,8 The major feature that distinguishes micelles from other drug delivery systems is that they apply not only to lipophilic drugs but also to hydrophilic drugs.”
Cyclosporine-loaded micelles for ocular delivery: investigating the penetration mechanisms
Ghezzi, M., Ferraboschi, I., Delledonne, A., Pescina, S., Padula, C., Santi, P., Sissa, C., Terenziani, F., & Nicoli, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.07.019 · Cited by 63
Terreni, E., Chetoni, P., Tampucci, S., Burgalassi, S., Al-kinani, A., Alany, R., & Monti, D. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030253 · Cited by 53
Self-assembling tacrolimus nanomicelles for retinal drug delivery
Gote, V., Mandal, A., Alshamrani, M., & Pal, D. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111072 · Cited by 39
Alambiaga-Caravaca, A. M., Calatayud-Pascual, M. A., Rodilla, V., Concheiro, A., López-Castellano, A., & Alvarez-Lorenzo, C. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12080702 · Cited by 38
Alami-Milani, M., Zakeri-Milani, P., Valizadeh, H., Fathi, M., Salatin, S., Salehi, R., & Jelvehgari, M. (2020) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2020.1733606 · Cited by 36
Wu, H., Xu, Y., Cai, M., You, L., Liu, J., Dong, X., Yin, X., Ni, J., & Qu, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061277 · Cited by 18
From design to Deployment: The innovative role of nanomicelles in targeted ophthalmic therapeutics
Sun, M., Wang, J., Fan, W., Wang, K., Wang, Y., Zhang, J., Ding, S., Zhang, C., Feng, Z., Wang, Y.-G., et al. (2025) · Materials today. Bio · doi:10.1016/j.mtbio.2025.102537 · Cited by 7
“Additionally, the instilled volume can stimulate reflex tearing, which dilutes the drug and accelerates its drainage via the nasolacrimal duct, resulting in low bioavailability [16].”
Dong, X., Cong, K., Lu, Y., Yang, S., Sun, Y., Hao, J., Liu, Y., Zhang, Y., Liu, C., He, C., et al. (2026) · Small · doi:10.1002/smll.74981
Metadata
- Authors
- Bachu, R., Chowdhury, P., Al-Saedi, Z., Karla, P., & Boddu, S.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2018-02-27
- Volume
- 10
- Issue
- 1
- Pages
- 28
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W2792337208
- Cited by
- 421
- References
- 165
- FWCI
- 12.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.